Enfortumab vedotin targets nectin-4 on the cell surface; after internalization, MMAE is released and binds beta-tubulin (vinca site) to inhibit microtubule polymerization, causing G2/M arrest and apoptosis. Cells expressing beta-tubulin alone are not selectively killed without nectin-4–mediated uptake.